Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir.
Bichoupan K; Schwartz JM; Martel-Laferriere V; Giannattasio ER; Marfo K; Odin JA; Liu LU; Schiano TD; Perumalswami P; Bansal M; Gaglio PJ; Kalia H; Dieterich DT; Branch AD; Reinus JF; Alimentary Pharmacology & Therapeutics, 2014, vol. 39, issue 2, p 209, ISSN 13652036. ISBN 13652036.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef